About this trial
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
Eligibility criteria
Qualifiers
Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
≥18 years, children under the age of 18 will be excluded due to rarity of disease
Physician's clearance to participate in moderate-vigorous intensity exercise
Disqualifiers
Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
Trial design
Treatments tested in this trial
- Exercise
- Attention Control